Highly Sensitive Lanthanide-Doped Nanoparticles-Based Point-of-Care Diagnosis of Human Cardiac Troponin I

Cardiac troponin I (cTnI) has been regarded as a gold standard for early diagnosis and prognosis monitoring of acute myocardial infarction (AMI) in clinical practice. Owing to its low concentration in blood, accurate determination of cTnI often requires high sensitivity. However, current established...

Full description

Saved in:
Bibliographic Details
Published in:International journal of nanomedicine 2022-01, Vol.17, p.635-646
Main Authors: Chen, Lu, Zhou, Shan-Yong, Zhu, Wei, Liu, Sheng-Ping, Zhang, Jing-Xi, Zhuang, He, Zhang, Jing-Ling, Li, Yong-Sheng, Gao, Fei
Format: Article
Language:English
Subjects:
Antibodies
Biomarkers
cardiac troponin i
Diagnosis
gdvo4:30% eu nps
Heart attack
Heart attacks
Humans
Lanthanoid Series Elements
lateral flow test strip
Nanoparticles
Original Research
Point-of-Care Systems
point-of-care test
Prognosis
Rare earth metals
Reproducibility of Results
Troponin I
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiac troponin I (cTnI) has been regarded as a gold standard for early diagnosis and prognosis monitoring of acute myocardial infarction (AMI) in clinical practice. Owing to its low concentration in blood, accurate determination of cTnI often requires high sensitivity. However, current established point-of-care (POC) assays are insufficient to meet clinically analytical requirements due to their low sensitivity. To this end, we established a highly sensitive and reliable POC lateral flow strip based on lanthanide-doped nanoparticles (NPs) for cTnI determination in human blood samples. The capture of cTnI on the lateral flow strip was performed in a sandwich assay, where Eu -doped vanadate nanoparticles (GdVO :30% Eu NPs) were used as luminescent probes to allow quantification. Our platform realized the analytical sensitivity enhancement with limit-of-detection (LOD) as low as 17 pg mL for cTnI detection, which was lower than the commercial counterpart; meanwhile, it displayed high specificity, excellent reproducibility and outstanding accuracy for analyzing clinical serum samples. Overall, this strategy provided an ultrasensitive, cost-effective and user-friendly platform for on-site cTnI detection, demonstrating the prospect of lanthanide-doped NPs-based POC diagnosis of disease-related biomarkers.
ISSN:1178-2013
1176-9114
1178-2013
DOI:10.2147/IJN.S346415